Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CD5 Plus data

XOMA presented data from a three-year, single-center Phase III trial in patients who had received allogeneic marrow transplants. CD5 Plus failed to demonstrate a

Read the full 243 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE